{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:23:52Z","timestamp":1791869032680,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.radonc.2015.08.015","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T14:13:30Z","timestamp":1441376010000},"page":"240-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C"],"prefix":"10.1016","volume":"117","author":[{"given":"Evan C.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Aleshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston W.","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroor R.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2015.08.015_b0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.radonc.2015.08.015_b0010","doi-asserted-by":"crossref","unstructured":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348: 1049\u201354.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"10.1016\/j.radonc.2015.08.015_b0015","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.08.015_b0020","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2015.08.015_b0025","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.08.015_b0030","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2015.08.015_b0035","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Anal Carcinoma, Version 2. 2014. (Accessed at <www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf>)."},{"key":"10.1016\/j.radonc.2015.08.015_b0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2015.08.015_b0045","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.08.015_b0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.08.015_b0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brachy.2004.06.003","article-title":"Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience","volume":"3","author":"Hwang","year":"2004","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2015.08.015_b0060","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0360-3016(96)00596-2","article-title":"Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal","volume":"37","author":"Peddada","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.08.015_b0065","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/infdis\/jir637","article-title":"Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study","volume":"204","author":"Nyitray","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.radonc.2015.08.015_b0070","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1007\/s10350-005-0098-5","article-title":"Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients","volume":"48","author":"Grabenbauer","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.radonc.2015.08.015_b0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2014.11.013","article-title":"Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer","volume":"113","author":"Koerber","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.08.015_b0080","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO\u2013ESSO\u2013ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.08.015_b0085","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.radonc.2014.10.002","article-title":"Anal carcinoma \u2013 survival and recurrence in a large cohort of patients treated according to Nordic guidelines","volume":"113","author":"Leon","year":"2014","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015004405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015004405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T18:28:02Z","timestamp":1537381682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814015004405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0167814015004405"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2015.08.015","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2015.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}